Radiotheranostics Market Size & Growth Forecast 2026–2035, By Segments (Approach, Radioisotope, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Radiotheranostics Market size stood at USD 10.44 Billion in 2025 and is predicted to grow at a 13.3% CAGR from 2026 to 2035, surpassing USD 36.39 Billion by 2035. The industry revenue for 2026 is estimated at USD 11.68 billion.

• Base Year Value (2025): USD 10.44 Billion
• CAGR (2026-2035): 13.3%
• Forecast Year Value (2035): USD 36.39 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Radiotheranostics Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America held a 54.23% share in 2025, supported by advanced nuclear medicine infrastructure, established clinical workflows, and strong industry participation driving adoption and commercialization.
  • Europe is projected to grow at a 14.9% CAGR as precision oncology adoption increases and hospitals expand the use of integrated molecular imaging and targeted therapeutic workflows.

• Segment Momentum:

  • Targeted Therapeutic held a 64.43% share in 2025 because it combines molecular targeting with treatment delivery, supporting precise, patient-specific care and expanding use within established clinical workflows.
  • 18F with Y-90 is growing fastest because it supports an integrated imaging-to-therapy pathway, helping clinicians improve treatment planning and advance precision-focused radiotheranostic workflows.

• Market Expansion Drivers:

  • Integration of molecular imaging with targeted radionuclide therapy enabling precision oncology treatment selection.
  • Expanding clinical validation and regulatory approvals accelerating radiopharmaceutical adoption in oncology centers.
  • AI-enabled dosimetry and imaging analytics improving personalized radiotheranostic treatment planning efficiency.

• Leading Market Participants:

  Top players in the radiotheranostics market include Novartis AG (Switzerland), Bayer AG (Germany), Lantheus Holdings, Inc. (United States), Telix Pharmaceuticals Limited (Australia), POINT Biopharma Global Inc. (United States), Fusion Pharmaceuticals Inc. (Canada), Actinium Pharmaceuticals, Inc. (United States), RadioMedix, Inc. (United States), SHINE Technologies, LLC (United States), NorthStar Medical Radioisotopes, LLC (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 10.44 Billion
  • 2026 Market Size: USD 15.2 billion
  • Projected Market Size: USD 36.39 Billion by 2035
  • Growth Forecasts: 13.3% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Europe
  • Core Revenue Segment: Targeted Therapeutic (Approach) | Lutetium-177 (Radioisotope) | Oncology (Application)
  • Emerging Opportunity Segment: Targeted Therapeutic (Approach) | 18F with Y-90 (Radioisotope) | Oncology (Application)

Market Growth Drivers and Industry Trends

Integration of molecular imaging with targeted radionuclide therapy enabling precision oncology treatment selection

The integration of diagnostic imaging and therapeutic radionuclides is shaping purchasing and treatment decisions in the radiotheranostics market by allowing oncology teams to identify suitable patients before therapy is initiated. Molecular imaging reveals target expression, lesion distribution, and disease burden with a level of specificity that supports therapy selection based on biological suitability rather than broad tumor classification alone. This connection between imaging and treatment is increasing demand for the radiotheranostics market because it makes radiopharmaceutical use more actionable in routine oncology practice, strengthens physician confidence in patient stratification, and encourages investment in coordinated imaging-therapy workflows at centers seeking more precise cancer treatment pathways.

Expanding clinical validation and regulatory approvals accelerating radiopharmaceutical adoption in oncology centers

As clinical evidence becomes more established and more products receive regulatory clearance, the radiotheranostics market benefits from a clearer path from specialist use to broader institutional adoption. Oncology centers are more willing to commit to radiopharmaceutical programs when published outcomes, safety data, and approved indications reduce uncertainty around treatment protocols, reimbursement discussions, and multidisciplinary care integration. This expanding validation is supporting market expansion by lowering the barriers that often delay hospital procurement, physician referral behavior, and infrastructure planning, especially where nuclear medicine capabilities must be aligned with oncology service lines.

AI-enabled dosimetry and imaging analytics improving personalized radiotheranostic treatment planning efficiency

AI-enabled dosimetry and imaging analytics are influencing market adoption by making personalized treatment planning more operationally feasible for providers managing complex radiotheranostic workflows. In the radiotheranostics market, therapy planning often depends on interpreting imaging data, estimating radiation dose distribution, and adjusting treatment decisions to individual patient characteristics, tasks that can be time-intensive and dependent on highly specialized expertise. AI tools help standardize image analysis and dose estimation, which improves consistency in clinical decision-making and allows centers to handle greater case volume without proportionally increasing planning burden, contributing to market size growth as precision treatment becomes easier to implement in everyday oncology practice.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Integration of molecular imaging with targeted radionuclide therapy enabling precision oncology treatment selection	2.50%	High	North America, Europe	Medium	Mid Term
Expanding clinical validation and regulatory approvals accelerating radiopharmaceutical adoption in oncology centers	2.20%	High	North America, Europe	Medium	Near Term
AI-enabled dosimetry and imaging analytics improving personalized radiotheranostic treatment planning efficiency	1.80%	Moderate	North America, Europe	Emerging	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Europe (Fastest-Growing Region)

North America held the leading position in the radiotheranostics market in 2025, accounting for a 54.23% share. This leadership is backed by the region’s established nuclear medicine infrastructure, broad access to advanced diagnostic and therapeutic workflows, and the presence of major industry participants actively supporting product development and clinical adoption. In practice, these advantages help providers move radiotheranostic agents more efficiently from specialized imaging into targeted treatment pathways, supporting higher procedure volumes and stronger commercial uptake across the region.

Europe is projected to expand at a 14.9% CAGR over the forecast period in the radiotheranostics market, driven by accelerating adoption of precision oncology approaches and growing integration of theranostic protocols into hospital-based nuclear medicine practice. Growth is being aided by the region’s increasing emphasis on targeted cancer care, which is translating into wider use of molecular imaging to guide therapy selection and monitor response. As more treatment centers incorporate these workflows into routine oncology management, demand is rising across both diagnostic and therapeutic applications.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Developing	Developing
Cost-Sensitive Region	Low	High	Medium	High	High
Regulatory Environment	Restrictive	Neutral	Restrictive	Neutral	Neutral
Demand Drivers	Strong	Strong	Strong	Moderate	Moderate
Development Stage	Developed	Developing	Developed	Developing	Emerging
Adoption Rate	High	High	High	Medium	Medium
New Entrants / Startups	Moderate	Moderate	Moderate	Sparse	Sparse
Macro Indicators	Strong	Strong	Stable	Stable	Stable

Key Country Insights

United States

Clinical Translation Hub

The U.S. radiotheranostics market is supported by expanding clinical research, specialized treatment centers, and investments in targeted radiopharmaceutical development. Healthcare providers across the U.S. continue strengthening isotope supply, imaging integration, and multidisciplinary cancer care pathways.

Japan

Advanced Imaging Adoption

Japan integrates radiotheranostics with sophisticated diagnostic imaging capabilities to improve treatment planning and patient management. Healthcare institutions in Japan prioritize high-quality imaging infrastructure, regulatory compliance, and precision-based therapeutic applications.

South Korea

Isotope Production Focus

South Korea is strengthening radiotheranostics by expanding domestic radiopharmaceutical production and specialized oncology services. Medical providers in South Korea invest in modern imaging systems and collaborative clinical programs to support personalized cancer treatment approaches.

Germany

Precision Oncology Integration

Germany is advancing radiotheranostics through established nuclear medicine expertise and coordinated hospital networks. Organizations in Germany emphasize standardized clinical workflows, reliable isotope availability, and expanded access to personalized oncology treatments.

France

Nuclear Medicine Expansion

France continues integrating radiotheranostics into comprehensive cancer treatment programs through specialized nuclear medicine facilities. Healthcare organizations in France focus on clinical collaboration, radiopharmaceutical access, and optimized patient selection for targeted therapies.

Italy

Specialized Care Networks

Italy is expanding radiotheranostics through specialized oncology and nuclear medicine centers that support personalized treatment pathways. Institutions across Italy prioritize clinician expertise, coordinated diagnostics, and improved infrastructure for targeted radiopharmaceutical therapies.

Segment Leadership and Growth Trends

  Approach Segment Analysis: Targeted Therapeutic (Largest & Fastest-Growing Segment)

Targeted Therapeutic held a 64.43% share of the radiotheranostics market in 2025, reflecting its central role in linking molecular targeting with treatment delivery in a clinically actionable framework. Its leadership is underpinned by the practical value of combining patient-specific targeting with therapeutic intent, which aligns well with how radiotheranostics is used to identify, treat, and monitor disease through the same biological pathway. The same treatment-focused utility is also driving continued expansion, as demand builds around approaches that can move beyond diagnosis alone and support more precise intervention within established care pathways in the radiotheranostics market.

Radioisotope Segment Analysis: Lutetium-177 (Largest Segment) vs 18F with Y-90 (Fastest-Growing Segment)

Within the radiotheranostics market, Lutetium-177 accounted for a 37.76% share in 2025, making it the leading radioisotope segment. Its market leadership is backed by its established fit within theranostic workflows, where isotopes must function reliably within targeted treatment models rather than serve a purely diagnostic role. This practical compatibility with treatment-oriented applications helps sustain Lutetium-177 demand, especially in settings where radiotheranostics adoption depends on isotopes that integrate effectively into existing clinical and operational use patterns.

18F with Y-90 is emerging as the fastest-growing radioisotope segment in the radiotheranostics market because it supports a more connected diagnostic-to-therapy pathway than single-purpose isotope choices. Growth momentum is tied to the increasing preference for combinations that align imaging and therapeutic planning more closely, improving how clinicians evaluate targets and proceed toward treatment. Relative to alternatives that are more narrowly positioned, 18F with Y-90 benefits from this integrated use case, which is becoming more relevant as radiotheranostics applications expand toward more coordinated and precision-driven care models.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Approach	Targeted Therapeutic, Targeted Diagnostic	Targeted Therapeutic	Targeted Therapeutic
Radioisotope	Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, Others	Lutetium-177	18F with Y-90
Application	Oncology, Non-oncology	Oncology	Oncology

Competitive Landscape and Market Positioning

Major players in the radiotheranostics market:

1. Novartis AG (Switzerland)

2. Bayer AG (Germany)

3. Lantheus Holdings Inc. (United States)

4. Telix Pharmaceuticals Limited (Australia)

5. POINT Biopharma Global Inc. (United States)

6. Fusion Pharmaceuticals Inc. (Canada)

7. Actinium Pharmaceuticals Inc. (United States)

8. RadioMedix Inc. (United States)

9. SHINE Technologies LLC (United States)

10. NorthStar Medical Radioisotopes LLC (United States)

Advancements in targeted diagnostic and therapeutic integration are accelerating development in the radiotheranostics market. Strong research pipelines are enabling precision-focused treatment approaches that combine imaging and therapy capabilities. Collaborative research efforts are supporting faster clinical translation of emerging solutions. New therapeutic introductions are increasingly centered on improving treatment specificity and patient outcome optimization.

Industry Development/News

Company Name	Date	Key Development
NUCLIDIUM	Mar-26	NUCLIDIUM completed a CHF 26.4 million Series B extension, bringing total Series B funding to CHF 105 million. The capital is allocated to advance clinical development of its NU101 and NU201 radiotheranostic programs targeting metastatic castration-resistant prostate cancer and metastatic breast cancer, reinforcing its position in targeted nuclear medicine oncology pipelines and accelerating late-stage translational development.
Sarvodaya Healthcare; Oncidium Foundation	Mar-26	Sarvodaya Healthcare partnered with the Oncidium Foundation to introduce radiotheranostics-based nuclear therapy services for cancer treatment. The collaboration focuses on implementing precision-guided radiotheranostic approaches to improve treatment personalization and clinical outcomes, expanding access to targeted nuclear medicine therapies within oncology care delivery systems.
Actinium Pharmaceuticals	Mar-25	Actinium Pharmaceuticals advanced development of its ATNM-400 Actinium-225 antibody radioconjugate, demonstrating strong preclinical efficacy across multiple solid tumor models. The progress strengthens the company’s targeted alpha-emitter platform strategy and supports expansion of its radiotheranostic pipeline with potential broad oncology applicability across solid tumor indications.
SHINE Technologies	Oct-24	SHINE Technologies advanced isotope production and collaborative preclinical capabilities supporting radiotheranostics development. The initiative strengthens its role as a critical upstream supplier of medical isotopes, enhancing reliability of supply chains for diagnostic and therapeutic nuclear medicine applications and enabling downstream innovation across radiotheranostic pipelines.
Telix Pharmaceuticals Limited	Jul-24	Telix Pharmaceuticals progressed late-stage development and global rollout of PSMA-targeted imaging agents while advancing therapeutic candidates aligned with radiotheranostic care pathways. The company emphasized diagnostics-led commercialization strategies, positioning imaging agents as clinical entry points to support broader adoption of integrated diagnostic-therapeutic nuclear medicine platforms.
Sanofi; Orano Med	Oct-24	Sanofi partnered with Orano Med to advance next-generation radioligand therapies for rare cancers. The collaboration combines oncology and targeted alpha therapy expertise to accelerate development of radiotheranostic treatment approaches, supporting pipeline expansion in precision nuclear medicine for difficult-to-treat cancer indications.
Lantheus	Jun-24	Lantheus acquired global rights to 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2 radiopharmaceutical pairs from Life Molecular Imaging. The acquisition strengthens its radiotheranostics portfolio by integrating complementary diagnostic and therapeutic agents targeting prostate and breast cancer, enhancing its position in clinically advanced radiotheranostic development.
Ariceum Therapeutics	Jan-24	Ariceum Therapeutics submitted an application to the UK MHRA to initiate a Phase 1 clinical trial of 123I-ATT001 in recurrent glioblastoma. The development advances early-stage radiotheranostic evaluation in central nervous system oncology, expanding the application scope of targeted radiopharmaceutical therapies in aggressive tumor indications.
Telix Pharmaceuticals Limited; Merck KGaA	Jul-23	Telix Pharmaceuticals initiated a Phase I trial of TLX250 in combination with Merck KGaA’s peposertib for patients with solid tumors. The study evaluates combination therapy integrating targeted radiation with DNA damage response inhibition, advancing clinical exploration of synergistic radiotheranostic and oncology treatment approaches.
Novartis AG	Dec-22	Novartis AG received European Commission approval for Pluvicto (lutetium Lu-177 vipivotide tetraxetan) combined with androgen deprivation therapy for metastatic castration-resistant prostate cancer. The approval establishes regulatory validation for radioligand therapy in advanced prostate cancer, reinforcing commercialization of targeted radiotheranostic treatment pathways in Europe.